EGFR and non-small cell lung carcinoma: The phase III study (AURA 3) showed that osimertinib improved PFS over platinum combined chemotherapy in patients with EGFR T790M-positive NSCLC whose disease had progressed after EGFR-TKI treatment [8, 9].